Evidence map›Paper›PMID 25630806›Full record

ArticleDer Internist2015

[Monogenic and syndromic symptoms of morbid obesity. Rare but important].

S Wiegand, H Krude

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Internist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

S WiegandSozialpädiatrisches Zentrum (SPZ), Charité-Universitätsmedizin Berlin, Berlin, Deutschland.
H Krude
Charité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonogenic and syndromic obesity are rare diseases with variable manifestation. Therefore diagnosis is difficult and often delayed.

objectivesThe purpose of this work was to develop a clinical diagnostic algorithm for earlier diagnosis. MATERIAL AND

methodsAvailable publications for clinical symptoms and molecular defects of monogenic and syndromic obesity cases were evaluated.

resultsMonogenic and syndromic obesity can be expected in cases with early manifestation before the age of 5 years and a BMI above 40 or above the 99th percentile. Syndromic cases are mostly associated with a low IQ and dwarfism. Monogenic cases are associated with additional endocrine defects. Measurement of serum leptin proves the treatable leptin deficiency. Sequencing of the melanocortin-4 receptor gene (MC4R) allows diagnosis of the most frequent monogenic form of obesity. Treatment with a melanocyte-stimulating hormone (MSH) analog can be expected in the future. Early treatment of children with Prader-Willi syndrome can prevent severe obesity.

conclusionBecause in some cases treatment is available, monogenic and syndromic obesity should be diagnosed early. Based on the disease symptoms, serum leptin, and MC4R sequencing, a diagnostic algorithm is proposed, which can be used to diagnose cases of morbid obesity.

Indexed as

Child, PreschoolFemaleGenetic MarkersGenetic Predisposition to DiseaseGenetic TestingHumansInfant, NewbornLeptinMaleObesity, MorbidPolymorphism, Single NucleotideReceptor, Melanocortin, Type 4Symptom AssessmentSyndromeGenetic MarkersLeptinMC4R protein, humanReceptor, Melanocortin, Type 4

Identifiers

PMID25630806
OpenAlexW135053107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.